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Manchester, Manchester, UK
Mast cells (MCs) are recognized to participate in the regulation of innate and adaptive
immune responses. Owing to their strategic location at the host–environment interface,
they control tissue homeostasis and are key cells for starting early host defense against
intruders. Upon degranulation induced, e.g., by immunoglobulin E (IgE) and allergen-
mediated engagement of the high-affinity IgE receptor, complement or certain neu-
ropeptide receptors, MCs release a wide variety of preformed and newly synthesized
products including proteases, lipid mediators, and many cytokines, chemokines, and
growth factors. Interestingly, increasing evidence suggests a regulatory role for MCs in
inflammatory diseases via the regulation of T cell activities. Furthermore, rather than only
serving as effector cells, MCs are now recognized to induce T cell activation, recruitment,
proliferation, and cytokine secretion in an antigen-dependent manner and to impact on
regulatory T cells. This review synthesizes recent developments in MC–T cell interactions,
discusses their biological and clinical relevance, and explores recent controversies in this
field of MC research.
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Introduction
Mast cells (MCs) are among the most malleable and rapidly responding cells of the immune system.
Within seconds of activation, they release a multitude of preformed biologically active products, fol-
lowed bymarked changes in cytoplasmic composition and volume that enable reconstitution of their
morphology and cell content within hours (1, 2). Counterintuitively, this cell-regenerative phase
coincides with a striking wave of mediator synthesis and secretion. Therefore, tissue-resident MCs
have the potential to strongly shape their tissue microenvironment and direct cell–cell interactions
and immune cell responses even while running through a reconstitution phase, during which they
are relatively “refractory” to external stimuli.
Derived from either hematopoietic precursors or local, tissue-resident progenitors, mature MCs
represent a heterogeneous collective of long lived, granulated cells located in essentially all tissues,
which increase in number upon proliferation or increased recruitment, survival, and/or maturation
of MC progenitors (1–3). They are particularly abundant at barrier sites, such as the skin, lung, and
gut, and play an important role in defense against, and clearance of various pathogens (4, 5).
While the involvement of MCs in allergic/inflammatory reactions triggered by the crosslinking
of FcεRI-bound immunoglobulin E (IgE) by antigen has been characterized in detail (6), the extent
of MC function in autoimmune diseases is less well understood (7, 8). Upon activation, MCs release
a plethora of mediators, including growth factors, cytokines, and chemokines (e.g., IL-1, IL-6,
IL-8, IL-10, TNFα, VEGF, TGFβ, CCL2-4) as well as pro-inflammatory lipid mediators, such as
prostaglandins and leukotrienes. However, MCs are mostly known for the ability to degranulate and
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very rapidly release preformed mediators from cytoplasmic gran-
ules, such as vasoactive amines (histamine and serotonin), pro-
teoglycans (e.g., heparin), proteases (above all tryptases and chy-
mases), and some pre-stored cytokines (e.g., TNFα) (1, 2, 9).
As players in innate immunityMCs have the capacity to initiate
and amplify immune responses. Several lines of evidence have
demonstrated that MCs participate in the sensitization phase of
acquired immune responses via the secretion of mediators, which
sustain dendritic cell (DC) maturation, function, and recruitment
to the tissue or theirmigration to local draining lymph nodes (10).
However, MCs also exert important effector function since MCs
and T cells of different origin and subsets establish tight cell–cell
interactions and modulate their respective effector functions in a
bidirectional manner; this has been shown in a variety of models
(11–13). Interestingly, MCs can even present antigen to T cells in
a MHC class I- or class II-restricted mechanism (11, 13, 14).
This review focuses on MC-mediated regulation of T cell
responses (Figure 1) since this activity not only shows MCs to
be an important element of acquired immunity but also to play
a cardinal role in shaping, controlling, sustaining, or arresting
inflammatory responses at host–environment interfaces and, thus,
of major clinical relevance.
MCs as Regulators of CD4+ T Cell Effector
Functions
Historically, MCs have been associated with the regulation of Th2
immune responses, and as such their modulatory activities on
CD4+ T cells have been amply documented in many different
models (Figure 1A).
In 1993, theMecheri group reported thatmurine bonemarrow-
derived mast cells (BMMCs) displayed antigen-presenting cell
(APC) functions (15), with these findings later extended to MCs
of rat and human origin (16–18). Efficient BMMC antigen pre-
sentation to CD4+ T cells was shown to require expression of
the costimulatory molecules CD80 and CD86, which are induced
by IL-4 and granulocyte/macrophage-colony-stimulating factor
(GM-CSF). Interestingly, in their studies, interferon (IFN) γ com-
pletely abrogated this phenomenon (19, 20); this IFNγ effect could
FIGURE 1 | Receptors and mediators involved in the interaction between
mast cells (MCs) with CD4+ (A), CD8+ (B), and regulatory T cells
(Tregs) (C). (A) MCs promote the activation, proliferation, and cytokine
secretion (e.g., IL-22, IFNγ) of CD4+ T cells via MHC II and OX40L cell–cell
interactions and TNFα secretion. (B) MCs induce CD8+ T cell recruitment via
the release of chemokines (e.g., CCL5) and leukotriene B4. Furthermore,
MC-mediated CD8+ T cell activation requires MHC I/TCR, OX40L/OX40, and
4-1BBL/4-1BB receptors interaction. (C) The OX40/OX40L-directed interaction
between Treg and MCs and the histamine and IL-6 production by the latter
inhibit the suppressive Treg activity.
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be counteracted by FcεRI-mediated antigen endocytosis (21). In
contrast to the above study, IFNγ-primed mouse MCs in their
antigen-mediated interaction with CD4+ T cells were shown to
develop a functional immunological synapse (22).
More recently, Gaudenzio and colleagues (23) have defined
MCs as “tissue-localized” APCs, which (in inflamed human psori-
atic skin) are primed by locally produced IFNγ to present antigen
to experienced and recruited CD4+ T cells. IFNγ-primed human
MCs establish synaptic contacts with effector/memory CD4+ T
cells, thus inducing Th22 and IL-22+IFNγ+Th cell subsets via
the release of IL-6 and TNFα. Interestingly, in inflammatory
conditions in which both MCs and T cells are enriched, as seen
in psoriatic skin, the majority of IL-22+ and IFNγ+CD4+ T cells
are in close contact with MCs and the latter act as amplifiers of
inflammation (23).
Since IL-6 and TNFα are mediators commonly released by
activated MCs upon a wide range of stimuli, it remains unclear
whether the IFNγ-induced MC search for immune partners is
broad or restricted to a specific cell type or T cell subset; and
how this encounter is spatially and temporally controlled. Fur-
thermore, whether this cognate interaction leads to bidirectional
effector functions, which might shape long-term MC activities is
yet to be defined.
The antigen presentation activity of murine MCs and the
MC-dependent modulation of effector T cell functions correlates
with the induced expression of MHC class II molecules (14, 24)
together with the up-regulation of a wide variety of costimulatory
molecules, includingmembers of the B7 family (ICOS ligand, PD-
L1, and PD-L2) and the TNF/TNFR families (OX40L, CD153, Fas,
and 4-1BB) (25).
In conjunction with the secretion of TNFα, the up-regulation
of the costimulatory molecule OX40L, in particular, has been
demonstrated to be essential for the MC-CD4+ T cell crosstalk
andmodulation of effector T cell function (25). OX40L expression
was reported to be induced by exposure of mouse MCs to stimuli,
such as toll-like receptor (TLR) agonists and FcεRI engagement
(24). Furthermore, Notch signaling was shown to upregulate
MHC class II andOX40L expression onmouseMCs thus promot-
ing the proliferation CD4+ T cells and their differentiation into T
helper 2 cells producing IL-4, IL-5, IL-10, and IL-13 (26).
Interestingly, treatment of human MCs with type I IFNs had
the opposite effect of down-regulating both TNFα and OX40L
expression while inducing IL-10 and TGFβ production with the
consequence of restraining CD4+ T cell effector activities (27).
This latter report underlies the key role of the inflammatory
microenvironment in tightly controlling the outcome of MC–T
cell interactions, and also suggests that the antigen presentation
ability of MCs is possibly not intrinsic to this cell type but varies
in response to time and location.
Gong and colleagues have proposed that the antigen-presenting
property is restricted to an FcεRIhi, MHC II+, and c-kit+ mouse
MC subset (28). However, considering the plasticity of MCs, one
could interpret the FcεRIhi and MHC II+ expression on MCs
rather as a transitory “activation” state born of environmental
(allergen) or inflammatory pressure rather than as a bona fide
subset of MCs.
In vitro as well as in vivo MCs are a heterogeneous cell
population, and their MHC class II expression is variable and
inducible. However, MHC class II molecules are not confined
to a “professional” MHC class II compartment as it is found
in professional APCs, but are stored in mature and immature
forms in both lysosomal and secretory granules of MCs [Ref. (29);
reviewed in Ref. (11)]. Furthermore, it has been reported that
MC-mediated T cell activation is mediated via exosome release
(30). It is therefore tempting to speculate that antigen presenta-
tion in MCs may be the result of both direct cognate cell–cell
interactions between MCs and T cells and MC-secreted MHC
class II and costimulatorymolecule-loaded exosomes acting upon
T cells.
MCs as Modulators of CD8+ T Cell
Responses
Recent evidence has suggested a protective role for MCs in antivi-
ral immune responses (31–35). This is based on the observation
thatMCs are equippedwith a full repertoire of pattern recognition
receptors, including TLRs (36), which allow MCs to sense and
respond to most microbial components, including viruses.
Upon TLR engagement, mouse MCs are activated to secrete
chemokines, of which notably CCL5 can recruit effector CD8+
T cells (37). Reovirus-infected human MCs have been shown,
through release of chemokines including CCL3, CCL4, andCCL5,
to selectively recruit cytotoxic effector cells, thus suggesting their
ability to enhance viral immunity (31).
Furthermore, in a model of murine cytomegalovirus (CMV)
infection, activated MCs have been described to recruit CD8+
T cells to the lungs via CCL5 release and thus contribute to
a reduction in the viral load and the clearance of infection
(34). MC activation upon CMV infection is characterized by an
immediate TLR3/TRIF signaling-dependent phase and a delayed
TLR3/TRIF-independent pathway phase (38). In allergy models,
the MC-mediated recruitment of effector, but not central mem-
ory, CD8+ T cells to sites of inflammation was shown to be
dependent on the production of MC leukotriene B4 (39).
However, the interactions between MCs and CD8+ T cells go
far beyond that of chemokine-induced recruitment (Figure 1B).
MCs have been reported to be capable of antigen presentation
via MHC class I molecules to T cells following phagocytosis
and processing of bacterial antigens from live bacteria (40). Fur-
thermore, physical MC/CD8+ T-cell contacts have been demon-
strated in healthy human skin. In lesional skin from alopecia
areata (AA) patients, MCs display an activated phenotype promi-
nently expressing MHC class I and the costimulatory molecules
OX40L and 4-1BBL. Furthermore, abnormal MC numbers, effec-
tor functions, and increased interactions with CD8+ T cells were
observed in the grafted C3H/HeJ mouse model of AA and in a
recently developed humanized mouse model for AA (41). Here,
in a pathological inflammatory environment, activated MCs may
contribute to the collapse of hair follicle immune privilege by ini-
tiating/sustaining CD8+ T cell effector functions, thus promoting
the disease (41).
Importantly, MC initiated antigen-dependent and MHC class
I-mediated cross-presentation to CD8+ T cells has been shown
to regulate CD8+ T cell effector functions including pro-
liferation, cytokine secretion, and cytotoxic activity in vitro;
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this was supported by complementary in vivo studies in
which antigen-specific CD8+ T cell numbers were reduced
in MC-deficient mice, using the experimental autoimmune
encephalomyelitis (EAE)model (42). These studies support previ-
ously published evidence that MC-deficient mice not only display
defective CD4+ but also CD8+ T cell numbers in EAE (43) as well
as in Leishmania major infection (44).
A specific priming of CD8+ effector T cells in the tissue at the
site of inflammation, delivered by resident immune cells, such as
MCs, may also be a relevant strategy not only to, initially, promote
protective inflammation but also to control and limit excessive
and/or chronic cytotoxic activity. However, very little evidence
has been published to date on CD8+ T cell/MC interactions.
Therefore, closing this important gap in our understanding of
MCs functions in health and disease should be a prime future
research focus.
MCs as Suppressors of T Cell Effector
Functions
Mast cells are also able to suppress T cell effector functions,
namely, by their interaction with regulatory T cells (Treg)
(Figure 1C). Adoptive transfer of Tregs in a mouse model of
sepsis correlated with increased MC numbers (45). Furthermore,
MCs contribute to the induction of tolerance to alloantigens being
recruited to skin allografts in response to IL-9 secreted by Tregs
(46, 47).
In line with the previously reported finding that high-FcεRI
expression correlates with efficient antigen-presenting abilities
in MCs (24, 28), Treg cells down-regulate FcεRI expression in
MCs (48). Mouse MCs have been shown to secrete histamine and
IL-6 and to use the OX40/OX40L signaling pathway to inhibit
Treg functions and to thus promote optimal activation of effector
CD4+ and CD8+ T cells (49–52).
However, it remains unclear which conditions promote the sup-
pression of MC functions by Tregs versus the inhibition of Tregs
by MCs. Moreover, it is conceivable that, under some conditions,
MC activation may overcome Treg-mediated immunosuppres-
sion, promote the development of effective antitumor immunity,
and boost the immune response in the tissue, while a different
signaling environment may contribute to allograft tolerance in
transplantation. Only a better definition of the relevant molecu-
lar check points will clarify the mechanisms that underlie these
opposite functional outcomes and will identify promising targets
for therapeutic interventions.
Controversies in the Field
However, it should be acknowledged that the regulatory impact
of MCs on T cell functions is still a controversially debated field.
Namely, studies utilizing various MC-deficient mouse models
have claimed that MCs are non-essential for the regulation of
either CD4+ or CD8+ T cell immune responses (53, 54). Yet, this
does not necessarily exclude T cell-regulatoryMC activities under
physiological conditions.
Mast cell function has been classically studied using the MC-
deficient C57BL/6-KitW-sh/W-sh or KitW/W-V mice, whose MC
deficiencies arise through loss of function mutations affecting
Kit. However, these mice are limited in their usefulness by their
perturbed immune cell composition, as such a number of new
“Kit-independent” MC-deficient strains have been generated (53,
55, 56). These mice have the great advantage of deleting the MC
population without apparently affecting other immune popula-
tions, with the exception of basophils (strain dependent), and
have called into question findings originally obtained using Kit-
dependent MC-deficient mice.
Owing to the use ofmultiplemouse strains anddiseasesmodels,
the role of MCs in autoimmune diseases has been very contro-
versial, with some authors tending to conclude that MCs are gen-
erally dispensable in autoimmunity (53). However, very recently,
Schubert and colleagues investigated in more detail the function
of MCs in arthritis using different strains of MC-deficient mice
and in models, either based on autoreactive antibody transfer
or effector T cells (57). Interestingly, these authors found MCs
to be critically relevant in the T cell-dependent mouse model
of rheumatoid arthritis [collagen-induced arthritis (CIA)], while
being dispensable in the T cell-independent antibody-induced
arthritis model. In the CIA model, absence of MCs resulted in
dramatic loss of T cell expansion upon immunization and con-
comitant reduction in T cell cytokine responses (57). These recent
findings underscore the critical role of MCs in T cell-dependent
autoimmunity.
However, in a T cell-dependent spontaneous diabetes model,
using non-obese diabetic (NOD) mice, MCs failed to impact on
CD4+ and CD8+ T cell numbers measured at the onset of the
disease (54). However, this study left it unclear whether at later
time points during disease progression, i.e., when the phenotype
divergence between MC deficient and wild-type mice may be
greatest, or during spontaneous disease resolution, the absence or
presence of MCs would have impacted upon T cell responses and
clinical outcome.
Possibly, the most contentious issue has been the role of MCs
in multiple sclerosis (MS), particularly in the T cell-dependent
surrogate mouse model of EAE, with some studies arguing an
important role for MCs (58, 59), while another one claims that
they are dispensable (53). This controversial discussion has been
very important and productive in the sense that it has brought
to light the limitations in the use of each of the presently avail-
able MC-deficient mouse strains, and has underscored the urgent
need for standardized disease-induction protocols to improve data
reproducibility. Furthermore, these discrepancies have served to
acutely remind us of the constitutive difficulties one faces in
translating murine data to the human condition.
Conclusion and Perspectives
In this review, we have highlighted interactions between MCs
and T cells, which regulate adaptive immune responses and
have delineated that the antigen-presenting activity of tissue-
resident immune cells, such as MCs, is fundamental to the
maintenance of productive and protective inflammation. MCs
may also actively participate in the fundamental processes,
which minimize immune-mediated bystander damage to healthy
tissues.
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Wehave also reviewed the evidence thatMC canmodulate Treg
activities. However, the mechanisms and dynamics that inter-
rupt MC-mediated antigen presentation, down-regulate the MC-
induced amplification of T cell-dependent immune response, and
restore local Treg cell homeostasis, all remain to be dissected by
future research.
This review has closed with discussing contradictory results
and the ensuing controversial debate on the role of MC in exper-
imental autoimmune disease. It is important to keep in mind
that the conflicting findings were generated using different MC-
deficientmouse strains. This raises the pertinent questionwhether
models, which rely on the deletion of an entire cell population,
such as MCs, which are notoriously heterogeneous, highly plastic
and adaptable in nature, and excel in their capacity to rapidly
shift the spectrum of mediators released and surface markers
expressed in distinct signaling environments (e.g., homeostatic
versus inflammatory settings), are not overly simplistic. Can such
models possibly reflect the (very transitory) dynamics ofMC biol-
ogy in vivo? Therefore, the ultimate research tool for definitively
clarifying the contribution of MCs to the regulation of T cell
functions under physiological and pathological conditions, which
fully takes into account the dynamism and heterogeneity of MCs,
may still have to be developed.
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